| Literature DB >> 23658808 |
Olfa Saidi1, Nadia Ben Mansour, Martin O'Flaherty, Simon Capewell, Julia A Critchley, Habiba Ben Romdhane.
Abstract
BACKGROUND: In Tunisia, Cardiovascular Diseases are the leading causes of death (30%), 70% of those are coronary heart disease (CHD) deaths and population studies have demonstrated that major risk factor levels are increasing.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23658808 PMCID: PMC3643918 DOI: 10.1371/journal.pone.0063202
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Population sizes and death rates of CHD in Tunisia, 1997 and 2009.
| Gendre | Age group | Population (1000) | Death (number) | Death rates per 100,000 | % Change | ||||
| 1997 | 2009 | 1997 | 2009 | 1997 | 2009 | (Crude) | (Weighted by pop) | ||
|
|
| 733 | 866 | 10 | 11 | 1 | 1 | −11.1% | −3.5% |
|
| 549 | 670 | 34 | 82 | 6 | 12 | 100.3% | 24.1% | |
|
| 318 | 571 | 215 | 261 | 68 | 46 | −32.2% | −6.6% | |
|
| 261 | 330 | 334 | 426 | 128 | 129 | 0.9% | 0.1% | |
|
| 174 | 216 | 454 | 645 | 260 | 299 | 14.8% | 1.1% | |
|
| 61 | 95 | 333 | 713 | 543 | 753 | 38.7% | 1.3% | |
|
| 29 | 41 | 112 | 290 | 387 | 702 | 81.4% | 1.2% | |
|
|
|
|
|
|
|
|
|
| |
|
|
| 751 | 908 | 0 | 3 | 0 | 0 | ||
|
| 546 | 723 | 12 | 29 | 2 | 4 | 85.0% | 21.1% | |
|
| 329 | 574 | 55 | 52 | 17 | 9 | −46.0% | −9.1% | |
|
| 264 | 348 | 118 | 91 | 45 | 26 | −41.3% | −4.9% | |
|
| 201 | 227 | 194 | 271 | 96 | 119 | 24.2% | 1.9% | |
|
| 57 | 92 | 175 | 464 | 309 | 502 | 62.8% | 2.0% | |
|
| 28 | 39 | 60 | 294 | 215 | 757 | 252.9% | 3.4% | |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| ||
Deaths attributable to population risk factor changes in Tunisia 1997–2009.
| RISK FACTORS | Risk factor level | Risk factor change | Deaths prevented or postponed (DPPs) | % of Total mortality change | ||||
| 1997 | 2009 | Absolute | Relative | Best |
|
| ||
|
| 23.9% | 22.7% | 0.01 | −0.05 |
|
|
|
|
|
| 47.2% | 41.9% | 0.05 | 55 | ||||
|
| 1.5% | 4.3% | −0.03 | −40 | ||||
|
| 130.41 | 131.03 | −0.62 | 0.00 | − | − | − | − |
|
| 129.45 | 133.42 | −3.97 | −270 | ||||
|
| 131.33 | 128.75 | 2.59 | 65 | ||||
|
| 4.59 | 4.73 | −0.14 | −0.04 | − | − | − | − |
|
| 4.44 | 5.17 | −0.73 | −440 | ||||
|
| 4.73 | 4.31 | 0.43 | 100 | ||||
|
| 98.44% | 85.16% | 0.13 | −0.13 |
|
|
|
|
|
| 97.29% | 81.62% | 0.16 | 35 | ||||
|
| 99.53% | 88.54% | 0.11 | 10 | ||||
|
| 26.03 | 27.47 | −1.45 | 0.06 | − |
|
| − |
|
| 24.83 | 26.76 | −1.94 | −85 | ||||
|
| 27.17 | 28.15 | −0.98 | −20 | ||||
|
| 12.09% | 17.26% | −0.05 | 0.43 | − |
|
| − |
|
| 11.99% | 18.89% | −65 | |||||
|
| 12.20% | 15.70% | −10 | |||||
|
| − | − | − | − | ||||
Deaths prevented or postponed by medical & surgical treatments in TUNISIA in 2009.
| Treatmentuptake | Best DPPs |
|
| |
|
|
|
|
| |
| Community CPR | 5,0% | 0 |
|
|
| Hospital CPR | 50,0% | 12 |
|
|
| Thrombolysis | 20,4% | 13 |
|
|
| Aspirin | 94,8% | 46 |
|
|
| Beta blockers | 67,8% | 8 |
|
|
| ACE inhibitor | 71,6% | 16 |
|
|
| PTCA (STEMI) | 43,2% | 41 |
|
|
| CABG | 4,0% | 2 |
|
|
| Cardiac rehabilitation | 0,0% | 0 |
|
|
|
|
|
|
| |
| Aspirin&heparin | 66,1% | 59 |
|
|
| Aspirin | 29,0% | 16 |
|
|
| PG IIA/IIIB | 1,1% | 0 |
|
|
| CABG surgery | 4,2% | 5 |
|
|
| PTCA | 5,0% | 5 |
|
|
|
|
|
|
| |
| Aspirin | 91,9% | 95 |
|
|
| Beta blockers | 45,7% | 40 |
|
|
| ACE inhibitors | 54,0% | 39 |
|
|
| Statins | 53,6% | 39 |
|
|
| Warfarin | 0,0% | 44 |
|
|
| Rehabilitation including exercise | 5,4% | 0 |
|
|
|
|
|
|
| |
| Aspirin | 94,8% | 2 |
|
|
| Beta blockers | 39,1% | 1 |
|
|
| ACE inhibitors | 48,9% | 1 |
|
|
| Statins | 72,0% | 2 |
|
|
| Warfarin | 0,9% | 0 |
|
|
| Rehabilitation | 0,0% | 0 |
|
|
|
|
|
|
| |
| ACE inhibitors | 20,0% | 10 |
|
|
| Beta blockers | 50,0% | 44 |
|
|
| Spironolactone | 25,0% | 25 |
|
|
| Aspirin | 95,0% | 48 |
|
|
| Statins | 0,0% | 0 |
|
|
|
|
|
|
| |
| ACE inhibitor | 10,0% | 14 |
|
|
| Beta blockers | 21,7% | 67 |
|
|
| Spironolactone | 7,1% | 19 |
|
|
| Aspirin | 49,0% | 71 |
|
|
| Statins | 21,8% | 0 |
|
|
|
|
|
|
| |
|
|
|
|
| |
|
| 1170 |
|
| |
|
| 720 |
|
| |
|
|
|
|
|
Model validation: estimated versus observed changes in CHD deaths in Tunisia between 1997 and 2009.
| OBSERVED CHANGE 1997–2009 | MODEL ESTIMATES | Discrepancy | Model FIT | |
|
| −1 | 1 | −2 | −100% |
|
| −49 | −41 | −7 | 84% |
|
| −47 | 124 | −171 | −265% |
|
| −92 | −4 | −88 | 4% |
|
| −191 | −82 | −107 | 43% |
|
| −380 | −198 | −181 | 52% |
|
| −178 | −130 | −48 | 73% |
|
| − | − | − |
|
|
| −3 | −3 | 0 | 100% |
|
| −17 | −14 | −4 | 82% |
|
| 3 | 45 | −41 | 1500% |
|
| 27 | 64 | −38 | 237% |
|
| −77 | −53 | −25 | 68% |
|
| −289 | −179 | −110 | 62% |
|
| −234 | −211 | −23 | 90% |
|
| − | − | − |
|
|
| − | − | − |
|
Figure 2Proportional contributions of specific risk factor changes to trends in CHD deaths number in Tunisia 1997–2009- sensitivity analysis.
Figure 3Proportional contributions of specific treatments to trends in CHD deaths number in Tunisia 1997–2009- sensitivity analysis.